ArticleBreast cancer research and treatment2023

Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.

Dandan Zheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.